24/7 Market News Snapshot 30 April, 2025 – Regulus Therapeutics Inc. (NASDAQ:RGLS)

April 30, 2025

DENVER, Colo., 30 April, 2025 (www.247marketnews.com) – (NASDAQ:RGLS) are discussed in this article.
Regulus Therapeutics Inc. is experiencing a significant surge in pre-market trading, reflecting a remarkable increase of 134.09%, positioning its shares at approximately $7.889, compared to the previous close of $3.370. The trading volume has reached 1.33 million shares, indicating heightened investor interest. This bullish momentum may be attributed to the latest news surrounding Regulus’s innovative therapeutic advancements, making it a focal point in the biopharmaceutical sector.

In an important development, Novartis has announced plans to acquire Regulus Therapeutics for an estimated $0.8 billion upfront, along with potential additional payments of $0.9 billion tied to regulatory achievements. This acquisition underscores Novartis’s commitment to advancing treatment options for patients suffering from autosomal dominant polycystic kidney disease (ADPKD), a condition currently with limited therapeutic solutions.

At the heart of Regulus’s promising pipeline is farabursen, a next-generation oligonucleotide targeting microRNA-17. Following encouraging results from a Phase 1b trial, where farabursen demonstrated notable efficacy and safety profiles by achieving significant reductions in urinary polycystin and total kidney volume, the compound has garnered considerable attention. Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis, expressed enthusiasm about the acquisition, highlighting farabursen’s potential as a critical addition to their portfolio aimed at improving patient care in renal diseases.

The acquisition has received unanimous approval from both companies’ Boards, with Novartis set to initiate a tender offer for Regulus’s shares at $7 each. A contingent value right (CVR) will also be included, reflecting potential future clinical accomplishments. The transaction is expected to conclude in the latter half of 2025, contingent on standard regulatory conditions, while both companies maintain their respective operational independence during this transition. Novartis’s history of three FDA approvals within nine months further reinforces its commitment to enhancing patient outcomes in renal health.

Related news for (RGLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.